Establishing Multidisciplinary Clinical Pathways for Proactive, Individualized Treatment of Inflammatory Bowel Disease

Despite advances and the availability of different therapies for the treatment of IBD, many patients never achieve or maintain remission and/or are dissatisfied with aspects of their therapy. Selecting, intensifying, sequencing, or combining therapies in IBD can be challenging for clinicians, especially considering the number of novel targeted therapies available and the expanding role of patient-reported outcomes in individualization of therapeutic decision-making. In addition, the care paradigm has evolved to include treat-to-target (T2T) strategies and, most recently, time-dependent treatment targets.  

However, gastroenterologists report a myriad of barriers in adopting T2T strategies in routine clinical practice. Some are resource driven, with greater constraints in monitoring experienced by smaller clinical practices, but others are an absence of risk factors for patient stratification or prognostic criteria to inform treatment selection.

As the prevalence of IBD continues to increase, gastroenterology teams must continually assess and adapt to evolving therapeutic strategies to ensure proactive, targeted, and patient-centric treatment to improve outcomes. To support translation and implementation of the latest recommendations into routine clinical practice, this training program, modeled on the CDC Training of Trainers approach, provides learners with the tools and resources to facilitate peer-to-peer learning with their interprofessional clinical teams.
 
Educational Partner: Academy for Continued Healthcare Learning (ACHL)

Medium: Online Presentation

Commercial Support: Supported by educational grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC. and Takeda Pharmaceuticals U.S.A., Inc.

Target Audience

This activity is intended for gastroenterologists, gastroenterology-focused advanced practice providers, internists, clinical pharmacists, gastroenterology nurses, and other members of the multidisciplinary care team.

Learning Objectives

Upon completion of this activity, learners will be able to:

  • Apply proactive treat-to-target strategies to facilitate management of IBD and improve patient outcomes;
  • Use and interpret available and emerging biomarkers in clinical practice to facilitate use of precision medicine in the management of IBD;
  • Evaluate efficacy and safety data of emerging therapies with novel mechanisms of action for the management of IBD.
Additional information
ACGME/ABMS Core Competencies: 
Patient Care and Procedural Skills
Medical Knowledge
Practice-based Learning and Improvement
Interpersonal and Communication Skills
For more information, please contact:
CME Coordinator Contact Name: 
ACHL
CME Coordinator Contact Phone: 
877-444-8435 ext. 160
Summary
Activity opens: 
06/13/2025
Activity expires: 
06/13/2026
UNIVERSITY OF CHICAGO FACULTY
  Russell D. Cohen, MD, FACG, AGAF (Chair)
  Professor of Medicine, Pritzker School of Medicine
  Co-Director, Digestive Diseases Center
  Clinical Director, Inflammatory Bowel Disease Center
  Co-Director, Advanced IBD Fellowship Program


  David Choi, PharmD, BCACP
  Clinical Pharmacy Specialist – Gastroenterology
  Associate Director Inflammatory Bowel Disease Center



 
Disclosure Declarations
As a provider accredited by the ACCME, The University of Chicago Pritzker School of Medicine asks everyone in a position to control the content of an education activity to disclose all financial relationships with any ineligible companies. This includes any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Financial relationships are relevant if a financial relationship, in any amount, exists between the person in control of content and an ineligible company during the past 24 months, and the content of the education is related to the products of an ineligible company with whom the person has a financial relationship. Mechanisms are in place to identify and mitigate any relevant financial relationships prior to the start of the activity.

Additionally, The University of Chicago Pritzker School of Medicine requires Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration at first mention and where appropriate in the content.
Physician Credit
The University of Chicago Pritzker School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
 
The University Of Chicago Pritzker School Of Medicine designates this enduring activity for a maximum of 3 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

 
Physician assistants, nurse practitioners, and nurses may participate in this educational activity and earn a certificate of completion as AAPA, AANP, and ANCC accept AMA PRA Category 1 Credits™ through their reciprocity agreements.
Registration: To view this activity, visit the ACHL website.
If you are logged in, click on the "Complete Activity" button below!
 
Please login or create an account to proceed.